Table of Content

20 January 2011, Volume 6 Issue 01

Previous Issue    Next Issue

论著

Natural History of Moyamoya Disease in Adult Patients

HAN Cong;DUAN Lian;LI Zhi-Fang;SHI Wan-Chao;ZHAO Feng;FENG Jie;XIAN Peng;YANG Wei-Zhong;BAO Xiang-Yang;YANG Ri-Miao.

2011, 6(01):  15-19. 

Asbtract ( )   PDF (2144KB) ( )  

Related Articles | Metrics

Objective The study aims to clarify the incidence and clinical features of disease progression in adult moyamoya disease.Methods From Dec. 2002 to Oct. 2009, 85 adult Chinese patients were diagnosed with moyamoya disease without any operation (a median time is 36 months). The symptoms at onset of all the case experiences are transient ischemic attack (TIA). Of these, 5 patients lost to follow. Disease progression occurred in 39 of 80 patients (48.75% per patient) during the follow-up period. The progressive symptoms of 39 patients included infarct in 32 patients and intracranial bleeding in 7. The interval between their onset and disease progression is a mean period of 26 months (Q1 12 months, Q3 35.8 months). The patients without disease progression are 41 persons.To clarify the predictors of disease progression in adult moyamoya disease, univariate analysis were performed between the patients with and without disease progression. Subsequently, a multivariate logistic regression model was conducted to test the effect on disease progression.Results As the results of univariate analysis, there was a signifcant difference in onset age and TIA frequency change between the stable group(without disease progression)and the progression group(with disease progression)[32.0±8.0 years vs 35.7±6.8years (P<0.05; 36.6%(15/41) vs 69.2%(27/39)]. Multivariate logistic regression analysis showed that patients’TIA frequency change was an independent predictor of disease progression during follow-up periods (P<0.05). The odds ratio conferred by a male patient was 3.899(95%CI 1.537-9.889) for disease progression.Conclusion The incidence of disease progression in adult moyamoya disease is much higher than recognized before, and that who has a higher TIA frequency may be at higher risk for it.

综述

Antiplatelet Therapy for Ischemic Stroke or Transient Ischemic Attack of Non-Cardiac Origin

XU Jie;WANG Yi-Long.

2011, 6(01):  87-92. 

Asbtract ( )   PDF (1731KB) ( )  

Related Articles | Metrics

In all patients with cerebrovascular disease, ischemic stroke accounts for about 80%. Moreover, ischemic stroke patients, many of whom accompanied by multiple risk factors suffer high risk of stroke recurrence. In the secondary prevention of non-cardiac ischemic stroke / transient ischemic attack (TIA), the effcacy of anti-platelet therapy has been verifed by a large number of clinical studies, and was recommended by national guidelines of many countries. According to recent guideline and classical clinical trials, we make a review about the model of antiplatelet therapy for ischemic stroke or TIA of non-cardiac origin.